Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

 
• By Jessica Merrill

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.

Prostate-cancer
Detailed data on Lynparza in prostate cancer was presented at ESMO • Source: Shutterstock

More from Anticancer

More from Therapy Areas